All In Biotech

Drug Trial Radar · NCT07227818

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy of NBI-1117568 in Preventing Relapse of the Symptoms of Schizophrenia and to Assess the Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

560

Planned (sponsor's estimate)

Start

Dec 16, 2025

Primary completion

Jul 2029

Study completion Jul 2029

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Nov 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

Conditions

  • Schizophrenia

Interventions

  • NBI-1117568Drug

    Oral capsules

  • PlaceboDrug

    Oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time From Randomization to RelapseTime frame: Up to approximately 30 weeks

Locations

25 sites in 3 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Garden Grove, California · Recruiting

  • Neurocrine Clinical Site

    La Habra, California · Recruiting

  • Neurocrine Clinical Site

    Lemon Grove, California · Recruiting

  • Neurocrine Clinical Site

    Oceanside, California · Recruiting

  • Neurocrine Clinical Site

    Torrance, California · Recruiting

  • Neurocrine Clinical Site

    West Hills, California · Completed

  • Neurocrine Clinical Site

    Hollywood, Florida · Recruiting

  • Neurocrine Clinical Site

    Maitland, Florida · Recruiting

  • Neurocrine Clinical Site

    Miami, Florida · Recruiting

  • Neurocrine Clinical Site

    Miami, Florida · Recruiting

  • Neurocrine Clinical Site

    Tampa, Florida · Recruiting

  • Neurocrine Clinical Site

    West Palm Beach, Florida · Recruiting

  • Neurocrine Clinical Site

    Atlanta, Georgia · Recruiting

  • Neurocrine Clinical Site

    Boston, Massachusetts · Recruiting

  • Neurocrine Clinical Site

    Flowood, Mississippi · Recruiting

  • Neurocrine Clinical Site

    Marlton, New Jersey · Recruiting

  • Neurocrine Clinical Site

    Cedarhurst, New York · Recruiting

  • Neurocrine Clinical Site

    New York, New York · Recruiting

  • Neurocrine Clinical Site

    New York, New York · Withdrawn

  • Neurocrine Clinical Site

    The Bronx, New York · Recruiting

  • Neurocrine Clinical Site

    DeSoto, Texas · Recruiting

  • Neurocrine Clinical Site

    Bellevue, Washington · Recruiting

  • Neurocrine Clinical Site

    San Juan, Puerto Rico · Recruiting

  • Neurocrine Clinical Site

    Gornja Toponica, Serbia · Recruiting

  • Neurocrine Clinical Site

    Kragujevac, Serbia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.